Development of Alkontrol herbal for Treating Alcohol Abuse
开发用于治疗酒精滥用的 Alkontrol 草药
基本信息
- 批准号:9504564
- 负责人:
- 金额:$ 50万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-20 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccidentsAcuteAdverse effectsAlcohol abuseAlcohol consumptionAlcohol dependenceAlcoholic beverage heavy drinkerAlcoholismAlcoholsAttentionAwardBackBiological AssayBiological AvailabilityBiological MarkersBiotechnologyBotanicalsBusinessesCessation of lifeChinaClinical ResearchClinical TrialsCollaborationsDevelopmentDoseDrug KineticsFDA approvedFetal Alcohol SyndromeHeavy DrinkingHigh Pressure Liquid ChromatographyHomicideHospitalsHuman VolunteersIndividualInjuryInstitutional Review BoardsInternationalIsoflavonesKudzuLabelLaboratoriesLaboratory StudyLegal patentMeasuresMethodsModelingMonitorMorbidity - disease rateMotorNamesNational Institute on Alcohol Abuse and AlcoholismOutpatientsPatternPerformancePersonsPharmaceutical PreparationsPhasePlantsPlasmaPopulationPositioning AttributePrecipitationPreparationPrimary Health CareProceduresProcessProductionPropertyProtocols documentationPublic HealthPublishingPueraria lobataQuality ControlRampReportingResearch InfrastructureSafetySleep Wake CycleSmall Business Technology Transfer ResearchSourceStandardizationTestingTimeVertebral columnWorkalcohol abuse therapyalcohol seeking behavioralcohol use disorderanalytical methodassaultbinge drinkerbinge drinkingcollegecommercializationdaidzindrinkingefficacy studyhuman subjectmedical schoolsmedication complianceproduct developmentpuerarinsafety studyscale upsexual assaulttreatment durationurinary
项目摘要
This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia
International, Inc. (NPI) and McLean Hospital to initiate steps toward commercializing a isoflavone botanical
product for treating alcoholism. Excessive use of alcohol accounts for much of the public health burden related
to alcohol use disorders, including fetal alcohol syndrome, fatal motor crashes, accidents and homicides. On
college campuses alone, alcohol use results annually in almost 2,000 deaths, 100,000 sexual assaults,
600,000 injuries, and 700,000 assaults. For most, problematic drinking and its associated morbidity will not be
brought to the attention of Primary Care Professionals and so many go without treatment. This is precisely
where an OTC herbal product could have the greatest impact. An extract of kudzu (Pueraria lobata) has been
patented by McLean Hospital and licensed it to NPI under the name Alkontrol-herbal. Over the past 13 years,
our team has extensively studied this kudzu extract and demonstrated its safety and efficacy in healthy control
subjects as well as in heavy binge drinkers. The reason for pursuing the STTR mechanism is two-fold: 1) while
NPI has been able to produce enough product for our modest clinical studies, they are not in a position to ramp
up full production in order to support larger scale clinical trials; and 2) we have conducted and published 6
studies in human subjects, but we have yet to conduct a study in heavy drinkers who are alcohol-dependent
and are treatment-seeking. Thus, there is a significant need for this clinical trial to demonstrate efficacy in this
important population. The reason for the Fast Track approach is that we have already developed product,
licensed it to NPI, and have the backbone of a commercialization plan, but need fiscal support to develop the
processes needed to increase production of enough standardized product to support not only the clinical trial,
but to be able to meet the needs once the commercialization plan is implemented. Thus Phase I will be
focused on providing NPI with the infrastructure to scale up production of standardized, high quality Alkontrolherbal
while the clinical trial will be the major milestone of Phase II. Collectively, successful completion of these
two phases will pave the way for the commercialization of Alkontrol-herbal. Key milestones for Phase I include:
procure and authenticate Pueraria lobata from our source in China, perform GMP extraction and precipitation,
develop independent QC analytical protocols, optimize ratio of isoflavones, and finalize submission of an IND
for FDA-approved labeling and IRB applications. Phase II milestones include: scale up production of Alkontrolherbal,
isolate puerarin for standardization, develop a urinary biomarker for medication adherence and conduct
proof-of-concept clinical trial in treatment-seeking alcohol-dependent individuals.
该快速通道STTR奖的申请代表了Natural Pharmacia与
国际,Inc.(NPI)和McLean医院启动将异黄酮类植物商业化的步骤
治疗酒精中毒的产品。过度饮酒是造成公共卫生负担的主要原因
酒精使用障碍,包括胎儿酒精综合症、致命的车祸、事故和凶杀。在……上面
仅在大学校园,饮酒每年就导致近2000人死亡,10万人遭到性侵犯,
60万人受伤,70万人遇袭。对大多数人来说,有问题的饮酒及其相关的发病率不会
引起了初级保健专业人员的注意,因此许多人得不到治疗。这正是
其中非处方药产品可能会产生最大的影响。葛根的一种提取物已经被提取
由McLean医院申请专利,并以Alkontrol-Herbal的名义授权给NPI。在过去13年里,
我们的团队对葛根提取物进行了广泛的研究,并证明了它在健康控制中的安全性和有效性。
受试者和酗酒者也是如此。推行短期租赁权机制的原因有两个:1)
NPI已经能够为我们有限的临床研究生产足够的产品,他们还没有能力
全面投产,以支持更大规模的临床试验;以及2)我们进行并发布了6项
在人类受试者身上进行研究,但我们还没有对酗酒者进行研究
并且正在寻求治疗。因此,这项临床试验有很大的必要来证明这种治疗的有效性。
重要的人口。之所以采用Fast Track方法,是因为我们已经开发了产品,
将其许可给NPI,并拥有商业化计划的骨干,但需要财政支持来开发
工艺需要增加足够的标准化产品的生产,以不仅支持临床试验,
但一旦商业化计划实施,就能够满足需求。因此第一阶段将是
专注于为NPI提供基础设施,以扩大标准化、高质量香草的生产
而临床试验将是第二阶段的重要里程碑。总的来说,成功完成这些
两个阶段将为Alkontrol草药的商业化铺平道路。第一阶段的主要里程碑包括:
从我们中国产地的葛根中获取并鉴定,进行GMP提取和沉淀,
制定独立的QC分析方案,优化异黄酮类的比例,并最终提交IND
用于FDA批准的标签和IRB应用。第二阶段的里程碑包括:扩大Alkontrolherbal的生产,
分离葛根素用于标准化,开发尿液生物标记物用于药物依从性和行为
在寻求治疗的酒精依赖者中进行的概念验证性临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT E LUKAS其他文献
SCOTT E LUKAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT E LUKAS', 18)}}的其他基金
Defining individual differences in tobacco smokers using multimodal neuroimaging
使用多模式神经影像学定义吸烟者的个体差异
- 批准号:
9975677 - 财政年份:2015
- 资助金额:
$ 50万 - 项目类别:
Sex/Gender and Nicotine Addiction: Hormones, Behavior and Neuroimaging
性别与尼古丁成瘾:激素、行为和神经影像
- 批准号:
8596807 - 财政年份:2010
- 资助金额:
$ 50万 - 项目类别:
Citicoline-Induced Modulation of Cannabis Effects: Imaging & Mechanism of Action
胞二磷胆碱诱导的大麻效应调节:成像
- 批准号:
8049240 - 财政年份:2009
- 资助金额:
$ 50万 - 项目类别:
Citicoline-Induced Modulation of Cannabis Effects: Imaging & Mechanism of Action
胞二磷胆碱诱导的大麻效应调节:成像
- 批准号:
7782800 - 财政年份:2009
- 资助金额:
$ 50万 - 项目类别:
Citicoline-Induced Modulation of Cannabis Effects: Imaging & Mechanism of Action
胞二磷胆碱诱导的大麻效应调节:成像
- 批准号:
8247729 - 财政年份:2009
- 资助金额:
$ 50万 - 项目类别:
Citicoline-Induced Modulation of Cannabis Effects: Imaging & Mechanism of Action
胞二磷胆碱诱导的大麻效应调节:成像
- 批准号:
7653583 - 财政年份:2009
- 资助金额:
$ 50万 - 项目类别:
Project 4 - Chinese Herbal Medicine to Treat Alcohol & Drug Abuse
项目4——中药解酒
- 批准号:
6883598 - 财政年份:2004
- 资助金额:
$ 50万 - 项目类别:
Cannabis Dependence: Imaging and Medication Development
大麻依赖:影像学和药物开发
- 批准号:
6879349 - 财政年份:2004
- 资助金额:
$ 50万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 50万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 50万 - 项目类别:
Operating Grants